Azetidine hydrochloride → 4-[4-{3-[4-(azetidin-1-ylmethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-(2-fluorophenyl)-1H-1,2,3-triazol-5-yl]pyridine

HRID 219586

Reaktionsgleichung

Reaktionsgleichung von HRID 219586
[F:1][C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][C:3]=1[N:8]1[C:12]([C:13]2[CH:18]=[CH:17][N:16]=[CH:15][CH:14]=2)=[C:11]([C:19]2[O:23][N:22]=[C:21]([C:24]3[CH:31]=[CH:30][C:27]([CH:28]=O)=[CH:26][CH:25]=3)[N:20]=2)[N:10]=[N:9]1.Cl.[NH:33]1[CH2:36][CH2:35][CH2:34]1>>[N:33]1([CH2:28][C:27]2[CH:30]=[CH:31][C:24]([C:21]3[N:20]=[C:19]([C:11]4[N:10]=[N:9][N:8]([C:3]5[CH:4]=[CH:5][CH:6]=[CH:7][C:2]=5[F:1])[C:12]=4[C:13]4[CH:18]=[CH:17][N:16]=[CH:15][CH:14]=4)[O:23][N:22]=3)=[CH:25][CH:26]=2)[CH2:36][CH2:35][CH2:34]1

Komponenten

3

Edukt 2

HCID 12308726Azetidine hydrochlorideHCID 866481594-(5-(1-(2-fluorophenyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazol-3-yl) benzaldehyde

Produkt 1

HCID 596041924-[4-{3-[4-(azetidin-1-ylmethyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-(2-fluorophenyl)-1H-1,2,3-triazol-5-yl]pyridine

Versuchsvorschrift

The title compound was prepared following the procedure described for Example 94, but starting from 4-(5-(1-(2-fluorophenyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazol-3-yl)benzaldehyde, obtained as described in Example 113, Step 1, (100 mg; 0.24 mmol) and azetidine hydrochloride (45.4 mg; 0.48 mmol) to give Example 138 as a white solid. 1H NMR: (DMSO-d6, 400 MHz) δ 8.75 (2H, dd, J=4.6, 1.6 Hz), 7.96-7.87 (3H, m), 7.76-7.69 (1H, m), 7.61 (2H, dd, J=4.6, 1.6 Hz), 7.51 (4H, t, J=8.1 Hz), 3.67 (2H, s), 3.22 (4H, t, J=6.9 Hz), 2.04 (2H, m). LC/MS (Method C): 454 (M+H)+. HPLC (Method E) Rt 2.19 min (Purity: 96.2%).

Aufarbeitung

  1. customobtained

Quellen und Nachweise

ORD-Eintrag
ord-6e9e691ac4a244198157626024c3428b
Quelldatensatz
uspto-grants-2012_06
Patentnummer
US08202856B2

Verknüpfte Notizen

Wird geladen…